[The blood coagulation status and the immunochemical and clinical indices in patients with active rheumatism during treatment with nerobol].
Blood coagulation, immunobiochemical, and clinical characteristics were studied in patients with rheumatic fever running a protracted course treated by combined therapy including nerobol. To assess the therapeutic efficacy of nerobol, the patients were divided into 2 groups: Group 1 (30 patients) were administered combined antirheumatic therapy, Group 2 (30 patients) were administered the same + nerobol in a daily dose of 15 mg for 3-4 weeks. The findings evidence a positive effect of the drug on the status of patients in whom rheumatic fever runs a protracted course: blood procoagulative activity is reduced and anticoagulative activity elevated, blood immunobiochemical and clinical characteristics normalized.